F Bürki

754 total citations
15 papers, 107 citations indexed

About

F Bürki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, F Bürki has authored 15 papers receiving a total of 107 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in F Bürki's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (4 papers) and Gastric Cancer Management and Outcomes (3 papers). F Bürki is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (4 papers) and Gastric Cancer Management and Outcomes (3 papers). F Bürki collaborates with scholars based in France, Belgium and United States. F Bürki's co-authors include Esteban Cvitkovic, M Musset, Iciar Garcı́a Carbonero, Étienne Brain, M. Itzhaki, J.L. Misset, Ezequiel Goldschmidt, L. Mauriac, R Trèves and M. Marty and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

F Bürki

13 papers receiving 104 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F Bürki France	5	76	46	28	26	23	15	107
Heather P. Becker United States	3	85 1.1×	81 1.8×	15 0.5×	17 0.7×	14 0.6×	4	118
Marla Lipsyc United States	3	107 1.4×	46 1.0×	36 1.3×	25 1.0×	32 1.4×	6	141
Daniel Barrowdale United Kingdom	4	45 0.6×	28 0.6×	38 1.4×	86 3.3×	41 1.8×	5	131
Fiona Hoar United Kingdom	6	50 0.7×	57 1.2×	33 1.2×	15 0.6×	35 1.5×	9	136
Iolanda Capone Italy	6	55 0.7×	29 0.6×	31 1.1×	42 1.6×	34 1.5×	16	109
Nawal Kassem United States	6	52 0.7×	57 1.2×	20 0.7×	17 0.7×	32 1.4×	14	115
A. Kohls Germany	6	74 1.0×	62 1.3×	13 0.5×	18 0.7×	8 0.3×	13	104
Shu-Chen Huang United States	2	64 0.8×	43 0.9×	81 2.9×	74 2.8×	26 1.1×	2	139
Mario Domenico Rizzato Italy	8	48 0.6×	29 0.6×	31 1.1×	29 1.1×	21 0.9×	24	120
A. Torrella-Ramos Spain	4	114 1.5×	56 1.2×	54 1.9×	36 1.4×	9 0.4×	5	141

Countries citing papers authored by F Bürki

Since Specialization

Citations

This map shows the geographic impact of F Bürki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Bürki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Bürki more than expected).

Fields of papers citing papers by F Bürki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F Bürki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Bürki. The network helps show where F Bürki may publish in the future.

Co-authorship network of co-authors of F Bürki

This figure shows the co-authorship network connecting the top 25 collaborators of F Bürki. A scholar is included among the top collaborators of F Bürki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F Bürki. F Bürki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Trédan, Olivier, Philippe Follana, Isabelle Moullet, et al.. (2016). A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. Annals of Oncology. 27(6). 1020–1029. 19 indexed citations

Mineur, Laurent, Éric François, Stéfano Kim, et al.. (2016). Bevacizumab combined with 1st line chemotherapy in elderly patients (≥75 years-old) with metastatic colorectal cancer - Interim results according to the chemotherapy regimen (CASSIOPEE). Annals of Oncology. 27. vi182–vi182. 1 indexed citations

François, Éric, Stéfano Kim, F Bürki, et al.. (2016). Bevacizumab plus chemotherapy as first-line therapy for elderly patients with metastatic colorectal cancer: Interim results of the noninterventional CASSIOPEE study.. Journal of Clinical Oncology. 34(15_suppl). 3555–3555. 1 indexed citations

Smith, Denis, Pernelle Noïze, R. Lassalle, et al.. (2011). Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: Results of ETNA, a French cohort study.. Journal of Clinical Oncology. 29(4_suppl). 555–555. 4 indexed citations

Viens, Patrice, Philippe Bougnoux, O. Rixe, et al.. (2001). A phase II trial of a paclitaxel and oxaliplatin combination in advanced ovarian cancer patients pretreated with cisplatin or carboplatin ± taxanes: Preliminary results. European Journal of Cancer. 37. S323–S323. 2 indexed citations

Ychou, Marc, Jean-Yves Douillard, Philippe Rougier, et al.. (2000). Randomized Comparison of Prophylactic Antidiarrheal Treatment Versus No Prophylactic Antidiarrheal Treatment in Patients Receiving CPT-11 (Irinotecan) for Advanced 5-FU-Resistant Colorectal Cancer. American Journal of Clinical Oncology. 23(2). 143–148. 22 indexed citations

Brain, Étienne, J.L. Misset, Iciar Garcı́a Carbonero, et al.. (1997). Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. British Journal of Cancer. 75(9). 1360–1367. 42 indexed citations

Bürki, F. (1991). New French studies of clodronate in cancer-induced osteolysis. Bone. 12. S35–S35. 1 indexed citations

Bürki, F, Jean‐Michel Coindre, & L. Mauriac. (1987). Sclerotic bone metastases of prostatic origin and osteomalacia. Importance of a histomorphometry study.. PubMed. 243A. 569–71. 5 indexed citations

10.

Bürki, F & R Trèves. (1986). [Polyarthritis and cancer of the esophagus].. PubMed. 53(10). 547–9. 2 indexed citations

11.

Bürki, F, et al.. (1985). [Intradural disk hernia. Apropos of a case].. PubMed. 52(10). 591–2. 1 indexed citations

12.

Trèves, R, et al.. (1984). [Therapeutic or palliative embolization aimed at analgesia for bone metastases of renal origin].. PubMed. 51(1). 1–5. 3 indexed citations

13.

Trèves, R, et al.. (1984). [Acute polymyositis complicating rheumatoid arthritis treated with pyrithioxin].. PubMed. 51(5). 283–5. 1 indexed citations

14.

Trèves, R, et al.. (1984). [Speculative ameloriation of arthritis in Behcet disease with thalidomide. A case report].. PubMed. 51(10). 585–585. 3 indexed citations

15.

Bürki, F, et al.. (1983). [Bony localization in Waldenström's disease. Anatomopathological study. Apropos of a case].. PubMed. 50(2). 159–61.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact